American Century Companies Inc. Grows Position in McKesson Corporation $MCK

Key Points

• American Century Companies boosted its stake in McKesson by 113.4% in Q3, buying 15,560 shares to hold 29,278 shares valued at about $22.62 million.
• Analysts rate McKesson a consensus "Moderate Buy" (13 Buy, 4 Hold) with a consensus price target of $960.93, and several firms recently raised targets (e.g., Barclays to $1,050, TD Cowen to $1,012).
• McKesson reported a Q beat with EPS $9.34 and revenue $106.16B (up 11.4% YoY), set FY2026 guidance of $38.80–$39.20 EPS, and pays a quarterly dividend of $0.82 (annual $3.28, yield ~0.3%).

American Century Companies Inc. raised its holdings in shares of McKesson Corporation (NYSE:MCK - Free Report) by 113.4% during the third quarter, according to its most recent filing with the SEC. The firm owned 29,278 shares of the company's stock after purchasing an additional 15,560 shares during the period. American Century Companies Inc.'s holdings in McKesson were worth $22,619,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of MCK. GGM Financials LLC bought a new position in shares of McKesson in the 3rd quarter worth $25,000. State of Wyoming bought a new stake in shares of McKesson in the 2nd quarter valued at about $29,000. Hopwood Financial Services Inc. purchased a new position in shares of McKesson in the 3rd quarter worth approximately $31,000. Abound Wealth Management grew its position in shares of McKesson by 104.3% in the 3rd quarter. Abound Wealth Management now owns 47 shares of the company's stock worth $37,000 after buying an additional 24 shares during the last quarter. Finally, Delos Wealth Advisors LLC bought a new position in shares of McKesson during the 2nd quarter worth approximately $35,000. 85.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

MCK has been the subject of several recent analyst reports. Barclays raised their target price on shares of McKesson from $960.00 to $1,050.00 and gave the company an "overweight" rating in a research note on Wednesday, February 18th. Zacks Research cut McKesson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, November 25th. TD Cowen raised their price target on McKesson from $1,000.00 to $1,012.00 and gave the stock a "buy" rating in a report on Thursday, February 5th. Leerink Partners restated an "outperform" rating and set a $1,085.00 price objective on shares of McKesson in a report on Thursday. Finally, Evercore reaffirmed an "outperform" rating on shares of McKesson in a research report on Thursday. Thirteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, McKesson currently has a consensus rating of "Moderate Buy" and a consensus price target of $960.93.

Insider Activity

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the company's stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $955.00, for a total value of $313,240.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Leann B. Smith sold 190 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total transaction of $179,550.00. Following the sale, the executive vice president directly owned 2,989 shares in the company, valued at approximately $2,824,605. The trade was a 5.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 3,868 shares of company stock valued at $3,743,820 in the last three months. Corporate insiders own 0.08% of the company's stock.

McKesson Stock Performance

NYSE MCK opened at $941.19 on Tuesday. The firm has a market capitalization of $115.29 billion, a P/E ratio of 27.07, a PEG ratio of 1.48 and a beta of 0.38. The stock has a 50-day simple moving average of $884.77 and a two-hundred day simple moving average of $819.18. McKesson Corporation has a fifty-two week low of $633.53 and a fifty-two week high of $999.00.

McKesson (NYSE:MCK - Get Free Report) last issued its earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, topping analysts' consensus estimates of $9.19 by $0.15. The firm had revenue of $106.16 billion for the quarter, compared to the consensus estimate of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The company's revenue was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, analysts forecast that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, March 2nd. McKesson's payout ratio is currently 9.43%.

About McKesson

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.